Migraine is a highly prevalent neurological pain syndrome, and its management is limited
due to side effects posed by current preventive therapies. Calcitonin gene-related peptide …

Migraine is a highly disabling neurological condition, and preventative treatment still
remains problematic, due to aspecificity of the majority of the currently available prophylactic …

Calcitonin gene related peptide (CGRP) monoclonal antibodies (mAbs) have been the first
class of specifically developed preventive treatments for migraine. Clinical trials data …

Background Therapeutic monoclonal antibodies against the calcitonin gene‐related peptide
(CGRP) receptor or its ligand have changed the landscape of treatment options for migraine …

Introduction: Erenumab, a monoclonal antibody targeting the receptor of calcitonin gene
related peptide (CGRP), is the first disease-specific and mechanism-based treatment …

Objective: To review the pharmacology, efficacy, and safety of the calcitonin gene-related
peptide (CGRP) inhibitor erenumab for migraine preventive therapy. Data Sources: A …

Background Erenumab, a calcitonin gene‐related peptide (CGRP) receptor monoclonal
antibody, has been well tolerated with good efficacy for the preventive treatment of episodic …

In this review, the authors provide an overview of erenumab, a monoclonal antibody used for
the preventative treatment of episodic migraine by targeting the CGRP pathway …

Background The calcitonin gene-related peptide (CGRP) pathway is important in migraine
pathophysiology. We assessed the efficacy and safety of erenumab, a fully human …

Abstract Purpose of Review The purpose of the following review is to summarize the most
recent understanding of migraine pathophysiology, as well as of basic and clinical science …